Verona

• A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi … Ended recruitment
  2023-509635-89-00 9 2021-06-01 DIPSS-Intermediate or High Risk Myelofibrosis
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa … Ended recruitment
  2024-516868-28-00 4 2021-05-04 Ph+ Acute Lymphoblastic Leukemia
• Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended recruitment
  2023-505615-21-00 5 2021-04-28 Muscle Invasive Bladder Cancer
• A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto … Ended recruitment
  2023-503916-33-00 5 2021-03-24 Diffuse Large B-Cell Lymphoma (DLBCL)
• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended recruitment
  2023-507890-17-00 5 2021-02-22 Anemia associated with myeloproliferative neoplasm (MPN)-associated my
• A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended recruitment
  2023-508290-81-00 5 2020-12-18 Immunoglobulin G4-related disease (IgG4-RD)
• POLAR BEAR Ended recruitment
  2022-502887-19-00 5 2020-08-18 Diffuse Large B-Cell Lymphoma
• A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab … Ended recruitment
  2024-520123-83-01 4 2020-02-11 Patients with relapsed or refractory cHL that has not responded to, or
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors Ended recruitment
  2023-506832-33-00 5 2019-11-06 haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
• A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in pati … Ended recruitment
  2023-509463-24-01 4 2019-11-04 metastatic pancreatic cancer
• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Ended recruitment
  2023-507405-34-00 5 2019-08-07 First-line patients with advanced biliary tract cancers (BTC)
• A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended recruitment
  2023-506153-38-00 5 2019-07-11 High-risk localized or locally advanced prostate cancer
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended recruitment
  2023-505478-14-00 5 2019-05-09 Psoriatic Arthritis
• A Study of Avapritinib in Patients with Indolent and Systemic Mastocytosis Ended recruitment
  2024-512585-34-00 4 2019-02-27 Indolent Systemic Mastocytosis (ISM)
• A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended recruitment
  2023-509576-42-00 5 2019-02-21 Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
• This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen … Ended recruitment
  2023-510015-19-00 5 2019-02-11 Patients with histologically or cytologically documented muscle-invasi
• A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri … Ended recruitment
  2024-510976-19-00 5 2018-11-30 Patients with Unresectable Locally Advanced or Metastatic Urothelial C
• A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended recruitment
  2022-501817-29-00 5 2018-11-27 High Risk Non-muscle invasive bladder cancer
• Extended Access of Momelotinib for Subjects with Myelofibrosis Ended recruitment
  2023-508018-41-00 4 2018-07-27 Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended recruitment
  2023-506429-13-00 5 2018-05-02 Progressive multiple sclerosis (PMS)
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia

Showing 337–360 of 440 trials